Advertisement
Advertisement

TSHA

TSHA logo

Taysha Gene Therapies, Inc. Common Stock

4.32
USD
Sponsored
-0.26
-5.68%
Mar 26, 15:59 UTC -4
Closed
exchange

After-Market

4.35

+0.03
+0.69%

TSHA Earnings Reports

Positive Surprise Ratio

TSHA beat 11 of 22 last estimates.

50%

Next Report

Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
$1.03M
/
-$0.09
Implied change from Q4 25 (Revenue/ EPS)
-81.20%
/
+12.50%
Implied change from Q1 25 (Revenue/ EPS)
-55.20%
/
+12.50%

Taysha Gene Therapies, Inc. Common Stock earnings per share and revenue

On Mar 19, 2026, TSHA reported earnings of -0.08 USD per share (EPS) for Q4 25, beating the estimate of -0.09 USD, resulting in a 18.45% surprise. Revenue reached 5.49 million, compared to an expected 1.93 million, with a 184.67% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 11 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 1.03 million USD, implying an increase of 12.50% EPS, and decrease of -81.20% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Assembly Biosciences, Inc
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.66
Actual
$2.48
Surprise
+474.06%
logo
Sol-Gel Technologies Ltd. Ordinary Shares
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.39
Actual
-
Surprise
-
FAQ
For Q4 2025, Taysha Gene Therapies, Inc. Common Stock reported EPS of -$0.08, beating estimates by 18.45%, and revenue of $5.49M, 184.67% above expectations.
The stock price moved -- 0%, changed from $4.53 before the earnings release to $4.53 the day after.
The next earning report is scheduled for May 13, 2026.
Based on 11 analysts, Taysha Gene Therapies, Inc. Common Stock is expected to report EPS of -$0.09 and revenue of $1.03M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement